Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line
1993
Study of Etoposide Resistance in Human Leukaemic Cells
publication
Evidence: moderate
Author Information
Author(s): S. Patel, L.M. Fisher
Primary Institution: St George's Hospital Medical School, University of London
Hypothesis
What genetic changes contribute to etoposide resistance in human leukaemic cells?
Conclusion
The study found that a specific mutation in the TOP2a gene contributes to etoposide resistance in the CEM/VP-1 cell line.
Supporting Evidence
- CEM/VP-1 cells are 15-fold more resistant to etoposide than parental CCRF-CEM cells.
- The study identified a novel Lys-797 to Asn mutation in the TOP2a gene associated with drug resistance.
- CEM/VP-1 cells exhibit an atypical MDR phenotype with cross-resistance to other topo II inhibitors.
Takeaway
Researchers looked at how some cancer cells become resistant to a drug called etoposide. They found a change in a gene that helps the cells survive the drug.
Methodology
The study used cytogenetic analysis, PCR/DNA sequencing, and allele-specific hybridisation to investigate genetic changes in the CEM/VP-1 cell line.
Want to read the original?
Access the complete publication on the publisher's website